Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002997 | 0.85 | UHRF1 (0.53) | UHRF1KIF11TSHRDYRK1AALDH1A1 | |
| SCHEMBL16454307 | 0.82 | UHRF1 (0.48) | UHRF1DYRK1AALDH1A1CCR1CCR5 | |
| SCHEMBL2735689 | 0.82 | UHRF1 (0.48) | UHRF1TSHRDYRK1ACCR1CCR5 | |
| SCHEMBL30947587 | 0.82 | UHRF1 (0.48) | UHRF1DYRK1AALDH1A1CCR1CCR5 | |
| SCHEMBL10193125 | 0.82 | UHRF1 (0.48) | UHRF1DYRK1AALDH1A1CCR1CCR5 | |
| SCHEMBL25089926 | 0.82 | UHRF1 (0.48) | UHRF1DYRK1AKDM4ECCR1CCR5 | |
| SCHEMBL19454592 | 0.82 | UHRF1 (0.48) | UHRF1DYRK1AKDM4EKMT2AMEN1 | |
| SCHEMBL19413079 | 0.80 | UHRF1 (0.46) | UHRF1DYRK1AALDH1A1TDP1LMNA | |
| SCHEMBL23639388 | 0.80 | ADRA2A (0.43) | UHRF1ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL29497390 | 0.79 | NOS3 (0.57) | UHRF1ALDH1A1NOS3NOS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 622 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1172878-B1 | Non-aqueous electrolytic solution and secondary battery containing same | MITSUBISHI CHEM CORP (JP) | 2011-06-22 | — | — | EP | claimed |
| US-6767671-B2 | STABILITY; HEAT RESISTANCE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-27 | — | — | US | claimed |
| US-20020025477-A1 | Non-aqueous electrolytic solution and secondary battery containing same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-02-28 | — | — | US | claimed |
| EP-1172878-A2 | Non-aqueous electrolytic solution and secondary battery containing same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-01-16 | — | — | EP | claimed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043620-B2 | Benzazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043620-B2 | Benzazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118290328-A | Hydrocarbon pyridine and preparation method thereof | 北京师范大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| EP-0710688-A1 | HYDROXYSILYL-TERMINATED POLYOXYETHYLENE COMPOUND, QUATERNARY-SALT-TERMINATED BLOCK COPOLYMER, AND PERCUTANEOUS ABSORPTION PROMOTER | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5200488-A | POLYORGANOSILOXANE HAVING A QUATERNARY SALT AT ITS ONE TERMINAL AND PERCUTANEOUS ABSORPTION-PROMOTING AGENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0484857-A2 | Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-4871848-A | OIL, GAS WELLS CORROSION INHIBITORS | THE DOW CHEMICAL COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| US-4740320-A | REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4725373-A | CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-02-16 | — | — | US | disclosed |
| US-4724003-A | Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines | THE DOW CHEMICAL COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4676834-A | Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone | THE DOW CHEMICAL COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043620-B2 | Benzazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | UHRF1 2960/4885KIF11 3822/4885TSHR 4160/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | UHRF1 1680/4885KIF11 1631/4885TSHR 3994/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | UHRF1 2048/4885KIF11 3394/4885TSHR 3550/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | UHRF1 864/4885KIF11 4319/4885TSHR 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.